Management of ischemic stroke in the hyperacute phase

Panminerva Medica

Volumn 55, Issue 1, 2013, Pages 59-78

  Devos, D ^a   Sevin, M ^a   De Gaalon, S ^a   Lintia Gaultier, A ^a   Guillon, B ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Brain infarction; Endovascular procedures; Stroke; Thrombolytic therapy

Indexed keywords

ANIMAL; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DIAGNOSTIC IMAGING; ENDOVASCULAR SURGERY; FIBRINOLYTIC THERAPY; HUMAN; METHODOLOGY; PREDICTIVE VALUE; TIME; TIME TO TREATMENT; TREATMENT OUTCOME;

ANIMALS; BRAIN ISCHEMIA; DIAGNOSTIC IMAGING; ENDOVASCULAR PROCEDURES; HUMANS; PREDICTIVE VALUE OF TESTS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TIME-TO-TREATMENT; TREATMENT OUTCOME;

EID: 84878709277     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (114)

1. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol 2007;6:182-7.
2. Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 1999;354:1457-63.
3. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003;4:399-415.
4. Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischemia - the ischemic penumbra. Stroke 1981;12:723-5.
5. Moustafa RR, Baron JC. Pathophysiology of ischaemic stroke: insights from imaging, and implications for therapy and drug discovery. Br J Pharmacol 2008;153(suppl 1):S44-S54.
6. Saver JL. Time is brain-quantified. Stroke 2006;37:263-6.
7. Shuaib A, Mohammad AA, Saqqur M, Liebeskind DS. Collateral blood vessels in acute ischaemic stroke: a potential therapeutic target. Lancet Neurol 2011;10:909-21.
8. Qureshi AL, Kirmani JF, Sayed MA, Safdar A, Ahmed S, Ferguson R et al. Time to hospital arrival, use of thrombolytics, and in-hospital outcomes in ischemic stroke. Neurology 2005;64:2115-20.
9. Lichtman JH, Watanabe E, Allen NB, Jones B, Dostal J, Goldstein LB. Hospital arrival time and intravenous t-PA use in US academic medical centers, 2001-2004. Stroke 2009;40:3845-50.
10. Walter S, Kostopoulos P, Haass A, Keller I, Lesmeister M, Schlechtriemen T et al. Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial. Lancet Neurol 2012;11:397-404.
11. Derex L. Adeleine P, Nighoghossian N, Honnorat J, Trouillas P. Factors influencing early admission in a French stroke unit. Stroke 2002;33:153-9.
12. Goldstein LB, Edwards MG, Wood DP. Delay between stroke onset and emergency department evaluation. Neuroepidemiology 2001;20:196-200.
13. Pancioli AM, Broderick J, Kothari R, Brott T, Tuchfarber A, Miller R et al. Public perception of stroke warning signs and knowledge of potential risk factors. JAMA 1998;279:1288-92.
14. Robinson TG, Reid A, Haunton VJ, Wilson A, Naylor AR. The face arm speech test: does it encourage rapid recognition of important stroke warning symptoms? Emerg Med J 2012 [Epub ahead of print].
15. The European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25:457-507.
16. The ESCORTT group. The identification of acute stroke: an analysis of emergency calls. Int J Stroke 2012 [Epub ahead of print].
17. Nor A, McAllister C, Louw S, Dyker A, Davis M, Jenkinson D et al. Agreement between ambulance paramedic-and physician-recorded neurological signs using the Face Arm Speech Test (FAST) in acute stroke patients. Stroke 2004;35:1355-9.
18. Sairanen T, Soinila S, Nikkanen M, Rantanen K, Mustanoja S, Färkkilä M et al. Two years of Finnish Telestroke: thrombolysis at spokes equal to that at the hub. Neurology 2011;76:1145-52
19. Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev 2007: CD000197.
20. Candelise L, Gattinoni M, Bersano A, Micieli G, Sterzi R, Morabito A. Stroke-unit care for acute stroke patients: an observational follow-up study. Lancet 2007;369:299-305.
21. Diringer MN, Edwards DF, Mattson DT, Akins PT, Sheedy CW, Hsu CY et al. Predictors of acute hospital costs for treatment of ischemic stroke in an academic center. Stroke 1999;30:724-8.
22. Adams Jr. HP, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999;53:126-31.
23. Weir CJ, Murray GD, Adams FG, Muir KW, Grosset DG, Lees KR. Poor accuracy of stroke scoring systems for differential clinical diagnosis of intracranial haemorrhage and infarction. Lancet 1994;344:999-1002.
24. Moulin T, Cattin F, Crepin-Leblond T, Tatu L, Chavot D, Piotin M et al. Early CT signs in acute middle cerebral artery infarction: predictive value for subsequent infarct locations and outcome. Neurology 1996;47:366-75.
25. Chalela JA, Kidwell CS, Nentwich LM, Luby M, Butman JA, Demchuk AM et al. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet 2007;369:293-8.
26. Schellinger PD, Bryan RN, Caplan LR, Detre JA, Edelman RR, Jaigobin C et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Evidencebased guideline: The role of diffusion and perfusion MRI for the diagnosis of acute ischemic stroke: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010;75:177-85.
27. Fure B, Bruun Wyller T, Thommessen B. Electrocardiographic and troponin T changes in acute ischaemic stroke. J Intern Med 2006;259:592-7.
28. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med 1995;333:1581-87.
29. Lees KR, Bluhmki E, Von Kummer R, Brott TG, Toni D, Grotta JC et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695-703.
30. Wardlaw JM, Murray V, Berge E, Del Zoppo G, Sandercock P, Lindley RL et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and metaanalysis. Lancet 2012;379:2364-72.
31. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29.
32. Wahlgren N, Ahmed N, Dävalos A, Hacke W, Millän M, Muir K et al. Thrombolysis with alteplase 3-4.5 h after acute ischemic stroke (SITS-ISTR): an observational study. Lancet 2008;372:1303-9.
33. Ahmed N, Wahlgren N, Grand M, Hennerici M, Lees KR, Mikulik R et al. SITS investigators. Implementation and outcome of thrombolysis with alteplase 3-4.5h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010;9:866-74.
34. European Stroke Organisation. Update Guidelines January 2009 [Internet]. Available at http://www.eso-stroke.org/pdf/ESO-Extended-Thrombolysis-KSU.pdf [cited 2010, Apr. 5].
35. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr; American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009;40:2945-8.
36. Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008;39:1647-52.
37. Zinkstok SM, Roos YB; ARTIS investigators. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet 2012;380:731-7.
38. IST-3 collaborative group, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G et al. A. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012;379:2352-63.
39. Mackey J, Kleindorfer D, Sucharew H, Moomaw CJ, Kissela BM, Alwell K et al. Population-based study of wake-up strokes. Neurology 2011;76:1662-7.
40. Todo K, Moriwaki H, Saito K, Tanaka M, Oe H, Naritomi H. Early CT findings in unknown-onset and wake-up strokes. Cerebrovasc Dis 2006;21:367-71.
41. Song SS, Latour LL, Ritter CH, Wu O, Tighiouart M, Hernandez DA et al. A pragmatic approach using magnetic resonance imaging to treat ischemic strokes of unknown onset time in a thrombolytic trial. Stroke 2012;43:2331-5.
42. Mishra NK, Albers GW, Davis SM, Donnan GA, Furlan AJ, Hacke W et al. Mismatch-based delayed thrombolysis: a meta-analysis. Stroke 2010;41:e25-e33.
43. Schwamm LH, Holloway RG, Amarenco P, Audebert HJ, Bakas T, Chumbler NR et al. A review of the evidence for the use of telemedicine within stroke systems of care: a scientific statement from the American Heart Association/American Stroke Association. Stroke 2009;40:2616-34.
44. De Keyser J, Gdovinova Z, Uyttenboogaart M, Vroomen PC, Luijckx GJ. Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations. Stroke 2007;38:2612-8.
45. Lansberg MG, Albers GW, Wijman CA. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis 2007;24:1-10.
46. Tsivgoulis G, Alexandrov AV, Chang J, Sharma VK, Hoover SL, Lao AY et al. Safety and outcomes of intravenous thrombolysis in stroke mimics: a 6-year, single-care center study and a pooled analysis of reported series. Stroke 2011;42:1771-4.
47. Hommel M, Boissel JP, Cornu C, Boutitie F, Lees KR, Besson G et al. Termination of trial of streptokinase in severe acute ischaemic stroke. Lancet 1995;345:57.
48. Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012;366:1099-107.
49. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73.
50. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006;37:1227-31.
51. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009;8:141-50.
52. Lee KY, Han SW, Kim SH, Nam HS, Ahn SW, Kim DJ et al. Early recanalization after intravenous administration of recombinant tissue plasminogen activator as assessed by pre-and postthrombolytic angiography in acute ischemic stroke patients. Stroke 2007;38:192-3.
53. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003-11.
54. Lee M, Hong KS, Saver JL. Efficacy of intra-arterial fibrinolysis for acute ischemic stroke: meta-analysis of randomized controlled trials. Stroke 2010;41:932-7
55. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005;36:1432-8.
56. Bose A, Henkes H, Alike K, Reith W, Mayer TE, Berlis A et al. The Penumbra System: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am J Neuroradiol 2008;29:1409-13.
57. Saver JL, Jahan R, Levy EL, Jovin TG, Baxter B, Nogueira RG et al. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet 2012 380:1241-9.
58. Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW, Walker GA et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet 2012;380:1231-40.
59. Gupta R, Tayal AH, Levy EL, Cheng-Ching E, Rai A, Liebeskind DS et al. Intra-arterial Thrombolysis or stent placement during endovascular treatment of acute ischemic stroke leads to highest recanalization rate: Results of a multi-center retrospective study. Neurosurgery 2011;68:1618-23.
60. Jovin TG, Liebeskind DS, Gupta R, Rymer M, Rai A, Zaidat OO et al. Imaging-based endovascular therapy for acute ischemic stroke due to proximal intracranial anterior circulation occlusion treated beyond 8 hours from time last seen well: retrospective multicenter analysis of 237 consecutive patients. Stroke 2011;42:2206-11.
61. Lansberg MG, Straka M, Kemp S, Mlynash M, Wechsler LR, Jovin TG et al. MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol 2012;11:860-7.
62. Mazighi M, Meseguer E, Labreuche J, Amarenco P. Bridging therapy in acute ischemic stroke: a systematic review and metaanalysis. Stroke 2012;43:1302-8.
63. Rubiera M, Ribo M, Pagola J, Coscojuela P, Rodriguez-Luna D, Maisterra O et al. Bridging intravenous-intra-arterial rescue strategy increases recanalization and the likelihood of a good outcome in nonresponder intravenous tissue plasminogen activator-treated patients: a case control study. Stroke 2011;42:993-7.
64. Mazighi M, Serfaty JM, Labreuche J, Laissy JP, Meseguer E, Lavallée PC et al. Comparison of intravenous alteplase with a combined intravenous endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study. Lancet Neurol 2009, 8:802-9.
65. Mokin M, Kass-Hout T, Kass-Hout O, Dumont TM, Kan P, Snyder KV et al. Intravenous thrombolysis and endovascular therapy for acute ischemic stroke with internal carotid artery occlusion: a systematic review of clinical outcomes. Stroke 2012;43:2362-8.
66. Coull AJ, Lovett JK, Rothwell PM. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 2004;328:326.
67. International Stroke Trial Collaborative Group. The International Stroke Trial (1ST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569-81.
68. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20, 000 patients with acute ischaemic stroke. Lancet 1997;349:1641-9.
69. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007;6:961-9.
70. Dengler R, Diener HC, Schwartz A, Grond M, Schumacher H, Machnig T et al. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, openlabel, blinded-endpoint trial. Lancet Neurol 2010;9:159-66.
71. Lazzaro MA, Zaidat OO. Multimodal endovascular reperfusion therapies: adjunctive antithrombotic agents in acute stroke. Neurology 2012;78:501-6.
72. Adams Jr. HP, Effron MB, Tomer J, Davalos A, Frayne J, Teal P et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-H). Stroke 2008;39:87-99.
73. Siebler M, Hennerici MG, Schneider D, Von Reutem GM, Seitz RJ, Rother J et al. Safety of Tirofiban in acute Ischemic Stroke: the SaTIS trial. Stroke 2011;42:2388-92
74. Memon MZ, Natarajan SK, Sharma J, Mathews MS, Snyder KV, Siddiqui AH et al. Safety and feasibility of intraarterial eptifibatide as a revascularization tool in acute ischemic stroke. J Neurosurg 2011;114:1008-13.
75. Gubitz G, Sandercock P, Counsell C. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev 2004: CD000024.
76. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a metaanalysis of randomized controlled trials. Stroke 2007;38:423-30.
77. Cimino M, Gelosa P, Gianella A, Nobili E, Tremoli E, Sironi L. Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist 2007;13:208-13.
78. Mariucci G, Taha E, Tantucci M, Spaccatini C, Tozzi A, Ambrosini MV. Intravenous administration of pravastatin immediately after middle cerebral artery occlusion reduces cerebral oedema in spontaneously hypertensive rats. Eur J Pharmacol 2011;660:381-6.
79. Dimagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci 1999;22:391-7.
80. Amaro S, Chamorro A. Translational stroke research of the combination of thrombolysis and antioxidant therapy. Stroke 2011;42:1495-9.
81. Kikuchi K, Uchikado H, Morioka M, Murai Y, Tanaka E. Clinical neuroprotective drugs for treatment and prevention of stroke. Int J Mol Sci 2012;13:7739-61.
82. Yip HK, Tsai TH, Lin HS, Chen SF, Sun CK, Leu S et al. Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischemic stroke. Crit Care 2011;15:R40.
83. Lakhan SE, Pamplona F. Application of mild therapeutic hypothermia on stroke: a systematic review and meta-analysis. Stroke Res Treat 2012; Feb. 20 (published online).
84. Robinson T, Waddington A, Ward-Close S, Taub N, Potter J. The predictive role of 24-hour compared to causal blood pressure levels on outcome following acute stroke. Cerebrovasc Dis 1997;7:264-72.
85. Castillo J, Leira R, Garcia MM, Serena J, Blanco M, Davalos A. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke 2004;35:520-6.
86. Geeganage C, Bath PM. Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database Syst Rev 2008;4:CD000039.
87. Sandset EC, Bath P M W, Boysen G, on behalf of the SCAST Study Group. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011:377: 741-50.
88. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001;32:2426-32.
89. Rosso C, Corvol JC, Pires C, Crozier S, Attal Y, Jacqueminet S et al. Intensive versus subcutaneous insulin in patients with hyperacute stroke: results from the randomized INSULINFARCT trial. Stroke 2012;43:2343-9.
90. Hajat C, Hajat S, Sharma P. Effects of post stroke pyrexia on stroke outcome: a meta-analysis of studies in patients. Stroke 2000;31:410-4.
91. Correia M, Silva M, Veloso M. Cooling therapy for acute stroke. Cochrane Database Syst Rev 2009;1:CD001247.
92. Ronning OM, Guldvog B. Should stroke victims routinely receive supplemental oxygen? A quasi-randomized controlled trial. Stroke 1999;30:2033-7.
93. Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, Von Kummer R. 'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol 1996;53:309-15.
94. Manno EM, Nichols DA, Fulgham JR, Wijdicks EF. Computed tomographic determinants of neurologic deterioration in patients with large middle cerebral artery infarctions. Mayo Clin Proc 2003;78:156-60.
95. Oppenheim C, Samson Y, Manai R, Lalam T, Vandamme X, Crozier S et al. Prediction of malignant middle cerebral artery infarction by diffusion-weighted imaging. Stroke 2000;31:2175-81.
96. Hofmeijer J, Kappelle LJ, Algra A, Amelink GJ, Van Gijn J, Van Der Worp HB. Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicentre, open, randomized trial. Lancet Neurol 2009;8:326-33.
97. Vahedi K, Vicaut E, Mateo J, Kurtz A, Orabi M, Guichard JP et al. Sequential-Design, Multicenter, Randomized, Controlled Trial of Early Decompressive Craniectomy in Malignant Middle Cerebral Artery Infarction (DECIMAL trial). Stroke 2007;38:2506-17.
98. Jüttler E, Schwab S, Schmiedek P, Unterberg A, Hennerici M, Woitzik J et al. Decompressive Surgeryfor the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): a randomized, controlled trial. Stroke 2007;38:2518-25.
99. Vahedi K, Hofmeijer J, Juettler E, Vicaut E, George B, Algra A et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol 2007;6:215-22.
100. Chen CC, Cho DY, Tsai SC. Outcome and prognostic factors of decompressive hemicraniectomy in malignant middle cerebral artery infarction. J Chin Med Assoc 2007;70:56-60.
101. Schneck MJ. Hemicraniectomy for hemispheric infarction and the HAMLET study: a sequel is needed. Lancet Neurol 2009;8:303-4.
102. Paciaroni M, Agnelli G, Corea F, Ageno W, Alberti A, Lanari A et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke 2008;39:2249-56.
103. Park JH, Ko Y, Kim WJ, Jang MS, Yang MH, Han MK et al. Is asymptomatic hemorrhagic transformation really innocuous? Neurology 2012;78:421-6.
104. Koh MG, Phan TG, Atkinson JL, Wijdicks EF. Neuroimaging in deteriorating patients with cerebellar infarcts and mass effect. Stroke 2000;31:2062-7.
105. Camilo O, Goldstein LB. Seizures and epilepsy after ischemic stroke. Stroke 2004;35:1769-75
106. Martino R, Foley N, Bhogal S, Diamant N, Speechley M, Teasell R. Dysphagia after stroke: incidence, diagnosis, and pulmonary complications. Stroke 2005;36:2756-63.
107. Okubo PC, Fcibio SR, Domenis DR, Takayanagui OM. Using the National Institute of Health Stroke Scale to predict dysphagia in acute ischemic stroke. Cerebrovasc Dis 2012;33:501-7.
108. Chamorro A, Horcajada JP, Obach V, Vargas M, Revilla M, Torres F et al. The Early Systemic Prophylaxis of Infection After Stroke study: a randomized clinical trial. Stroke 2005;36:1495-500.
109. Kamphuisen PW, Agnelli G, Sebastianelli M. Prevention of venous thromboembolism after acute ischemic stroke. J Thromb Haemost 2005;3:1187-94.
110. Dennis M, Sandercock PA, Reid J, Graham C, Murray G, Venables G et al. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): A multicenter, randomized controlled trial. Lancet 2009;373:1958-65.
111. Geeganage CM, Sprigg N, Bath MW, Bath PM. Balance of symptomatic pulmonary embolism and symptomatic intracerebral hemorrhage with low-dose anticoagulation in recent ischemic stroke: A systematic review and meta-analysis of randomized controlled trials. J Stroke Cerebrovasc Dis 2012; Apr. 17 (Epub ahead of print).
112. Reddy M, Gill SS, Rochon PA. Preventing pressure ulcers: a systematic review. JAMA 2006;296:974-84.
113. Otterman NM, Van Der Wees PJ, Bernhardt J, Kwakkel G. Physical therapists' guideline adherence on early mobilization and intensity of practice at dutch acute stroke units: a country-wide survey. Stroke 2012;43:2395-401.
114. Veerbeek J, Koolstra M, Ket J C F, Van Wegen EH, Kwakkel G. Effects of augmented exercise therapy on outcome of gait and gait-related activities in the first six months after stroke: a meta-analysis. Stroke 2011;42:3311-5.